Bristol Myers Squibb, UbiVac to assess combination immunotherapy for advanced triple-negative breast cancer

This article was originally published here

The partnership will assess the safety, tolerability, and preliminary efficacy of UbiVac’s investigational product DRibble Platform Vaccine 001(DPV-001) in combination with BMS’ anti-OX40 (BMS-986178) combined with sequenced administration

The post Bristol Myers Squibb, UbiVac to assess combination immunotherapy for advanced triple-negative breast cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply